{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-21-022445","form_type":"8-K","ticker":"NAII","cik":"0000787253","company_name":"NATURAL ALTERNATIVES INTERNATIONAL INC","filed_at":"2021-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.758219+00:00","generated_at":"2026-06-29T02:28:35.594264+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NAI reports record FY2021 sales $178.5M, net income $10.8M; guides FY2022 sales up 5-10%","bullets":["Q4 net sales $44.4M (+26.5% YoY); diluted EPS $0.47 vs $0.27 prior year.","FY2021 net sales $178.5M (+50.2%); net income $10.8M vs net loss $1.6M in FY2020.","CarnoSyn royalty revenue up 102.6% in Q4; private-label manufacturing sales +54.6% for year.","FY2022 guidance: net sales +5-10% YoY; operating income 7-9% of sales; first half slower due to supply chain.","Appoints Dr. Guru Ramanathan (former GNC Chief Innovation Officer) as independent director."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-21-022445","json":"https://secwatch.observer/filing/0001437749-21-022445.json","markdown":"https://secwatch.observer/filing/0001437749-21-022445.md","text":"https://secwatch.observer/filing/0001437749-21-022445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/787253/000143774921022445/0001437749-21-022445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/787253/000143774921022445/naii20210920_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T02:28:35.594264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40433d0e05","claim":"Dr. Guru Ramanathan was appointed as Director at NATURAL ALTERNATIVES INTERNATIONAL INC.","evidence_excerpt":"The Board appointed Dr. Guru Ramanathan to complete the remaining term of the deceased director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/787253/000143774921022445/0001437749-21-022445-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}